RESEARCH COLLABORATION AND OPTION AGREEMENT between JANSSEN PHARMACEUTICALS, INC. and MORPHIC THERAPEUTIC, INC. DATED: FEBRUARY 15, 2019Research Collaboration and Option Agreement • June 14th, 2019 • Morphic Holding, Inc. • Pharmaceutical preparations • New York
This Research Collaboration and Option Agreement (this “Agreement”), dated as of February , 2019 (the “Effective Date”), is made by and between Morphic Therapeutic, Inc. having an office at 35 Gatehouse Drive A2, Waltham, MA 02451 92121 (“Morphic”), and Janssen Pharmaceuticals, Inc. having an office at 1125 Trenton-Harbourton Road, Titusville, NJ 08560 (“Janssen”). Each of Morphic and Janssen may be referred to herein as a “Party” or together as the “Parties.”
INTRODUCTIONResearch Collaboration and Option Agreement • June 2nd, 2000 • Curis Inc • Biological products, (no disgnostic substances) • Massachusetts
AMENDMENT NO. 1 TO RESEARCH COLLABORATION AND OPTION AGREEMENTResearch Collaboration and Option Agreement • March 1st, 2021 • Morphic Holding, Inc. • Pharmaceutical preparations
This Amendment No. 1 to Research Collaboration and Option Agreement (this “First Amendment”) is dated as of December 30, 2020 (the “Amendment Effective Date”) by and between:
Exhibit 10.1 Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. RESEARCH COLLABORATION AND OPTION AGREEMENT by and between HYBRIDON, INC.Research Collaboration and Option Agreement • August 9th, 2005 • Hybridon Inc • Biological products, (no disgnostic substances) • New York
Research COLLABORATION AND Option AGREEMENTResearch Collaboration and Option Agreement • February 7th, 2019 • Arrowhead Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
This Research Collaboration and Option Agreement (“Agreement”), made as of the date of execution by the last Party to sign below (the “Execution Date”) and effective as of the Effective Date as defined below, is by and between Arrowhead Pharmaceuticals, Inc., a Delaware corporation with a place of business at 225 South Lake Avenue, Suite 1050, Pasadena, California 91101, USA (“Arrowhead”), and Janssen Pharmaceuticals, Inc., a Pennsylvania corporation with a place of business at 1125 Trenton-Harbourton Road, Titusville, New Jersey 08560, USA (“Janssen”). Arrowhead and Janssen are at times referred to herein individually as a “Party” and collectively as the “Parties”.
CERTAIN INFORMATION IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED PURSUANT TO ITEM 601(B)(10)(IV) OF REGULATION S-K UNDER THE SECURITIES ACT OF 1933, AS AMENDED, BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO...Research Collaboration and Option Agreement • August 4th, 2021 • Morphic Holding, Inc. • Pharmaceutical preparations
This Amendment No. 2 to Research Collaboration and Option Agreement (this “Second Amendment”) is dated as of June 18, 2021 (the “Amendment Effective Date”) by and between:
RESEARCH COLLABORATION AND OPTION AGREEMENTResearch Collaboration and Option Agreement • May 2nd, 2019 • Seres Therapeutics, Inc. • Pharmaceutical preparations • Delaware
This RESEARCH COLLABORATION AND OPTION AGREEMENT (the “Agreement”) is made as of the date of last signature hereunder (the “Effective Date”), by and between MedImmune, LLC., a limited liability company organized and existing under the laws of Delaware, having an office located at One MedImmune Way Gaithersburg, MD 20878, USA (“MedImmune”), and Seres Therapeutics, Inc., a corporation incorporated and existing under the laws of the State of Delaware, having an office located at 200 Sidney Street, Cambridge, MA 02139, USA (“Seres”). MedImmune and Seres are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
CONFIDENTIAL TREATMENT REQUESTED Research Collaboration and Option AgreementResearch Collaboration and Option Agreement • May 15th, 2017 • Threshold Pharmaceuticals Inc • Pharmaceutical preparations • Massachusetts
This Research Collaboration and Option Agreement (this “Agreement”) is made effective as of October 31, 2016 (“Effective Date”) by and between Millennium Pharmaceuticals, Inc., with a principal office at 40 Landsdowne Street, Cambridge, MA 02139 (Telephone: 617-679-7000, Facsimile: 617-374-0074), a wholly-owned subsidiary of Takeda Pharmaceutical Company Ltd. (“Takeda”), and Molecular Templates, Inc. with a principal office at 9301 Amberglen Boulevard, Suite 100, Austin, TX 78729 (“MTI”). MTI and Takeda each will be referred to herein as a “Party” and together as the “Parties.”
